An Innovative Biopharmaceutical Company Advancing a Cutting-Edge Pipeline of Therapeutic Innovations

At Essen Biotech, we are committed to pioneering cutting-edge therapies that harness the power of the immune system to combat cancer, genetic disorders, and autoimmune diseases.
Our diverse pipeline encompasses a range of advanced therapies, including CAR-T, TILs, and CRISPR-Cas9 gene editing, aimed at transforming patient outcomes and providing hope to those battling life-threatening conditions.
From discovery through to clinical trials, our rigorous development process reflects our dedication to quality, safety, and efficacy in every stage. Explore our current pipeline to see how we are pushing the boundaries of modern medicine to bring tomorrow’s treatments to life today.

Target
Program
Trial
Indication
Development
CD19 / CD22
EB CAR-T
BAH421
Acute Lymphoblastic Leukemia (B-ALL)
ClinicalTrials ID
NCT06213636
Status
Phase 2
CD5 / CD7
EB CAR-T
BAH246
Acute T Cell Lymphoblastic Leukemia
ClinicalTrials ID
NCT06420076
Status
Phase 2
BCMA / CD19
EB CAR-T
BAH245
Multiple Myeloma (MM)
ClinicalTrials ID
NCT06532719
Status
Phase 2
CD33 / CD123
EB CAR-T
BAH244
Acute Myelocytic Leukemia (AML)
ClinicalTrials ID
NCT06420063
Status
Phase 2
TILs (CD8+/CD4+)
EB TILs
BAH2472
Advanced/Metastatic Refractory Lung Cancer
ClinicalTrials ID
NCT06538012
Status
Phase 2
TILs (CD8+/CD4+)
EB TILs
BAH249
Advanced/Metastatic Refractory Breast Cancer
ClinicalTrials ID
NCT06532812
Status
Phase 2
TILs (CD8+/CD4+)
EB TILs
BAH250
Metastatic Refractory Stomach & Esophageal Cancer
ClinicalTrials ID
NCT06532799
Status
Phase 2
TILs (CD8+/CD4+)
EB TILs
BAH248
Colon and Rectum Cancer
ClinicalTrials ID
NCT06530303
Status
Phase 2
TILs (CD8+/CD4+)
EB TILs
BAH2473
Malignant Glioma
ClinicalTrials ID
NCT06640582
Status
Phase 2
BCMA / CD19
EB CAR-T
BAH242
Systemic Lupus Erythematosus
ClinicalTrials ID
NCT06428188
Status
Phase 2
BCMA / CD19
EB CAR-T
BAH247
Multiple Sclerosis
ClinicalTrials ID
NCT06532799
Status
Phase 2
BCL11A Gene
EB CAS-9 LV
BAH243
Sickle Cell Disease (SCD)
ClinicalTrials ID
NCT06399107
Status
Phase 2
BCL11A Gene
EB CAS-9 LV
BAH243
Beta-Thalassemia
ClinicalTrials ID
NCT06399107
Status
Phase 2
Alpha-Globin (HBA)
EB CAS-9 LV
BAH244
Alpha-Thalassemia
ClinicalTrials ID
NCT06399107
Status
Phase 2

ESSEN BIOTECH Clinical Trials in Discovery Phase

Target
Program
Trial
Indication
Development
CTLs
EB CTL
EB CTL-1001
Various solid tumors and hematologic malignancies
Program
Cytotoxic T Lymphocytes (CTLs) Therapy
Status
Discovery
Mesenchymal Stem Cells
EB MSC
EB MSC-2001
Regenerative medicine and immune modulation
Program
MSC Stem Cell Therapy
Status
Discovery
Natural Killer (NK) Cells
EB NK
EB NK-3001
Hematologic and solid tumors
Program
NK Cell Immunotherapy
Status
Discovery
CD8+ / CD4+ PBLs
EB PBL
EB PBL-4001
Various solid and hematologic malignancies
Program
Peripheral Blood Lymphocyte (PBL) Therapy
Status
Discovery

Impact and Excellence

These numbers illustrate more than our capabilities—they embody our mission to bring transformative treatments to patients, foster innovation, and lead in the development of cutting-edge biotechnological solutions.
At Essen Biotech, we are driven by the belief that every milestone achieved translates to hope, progress, and improved outcomes for patients around the world.

Patient Enrollment Rate
% 0
Activate Clinical trials
+ 0
Patient Success Rate
% 0
Collaborative Partnerships
+ 0

Essen Biotech’s innovative therapies are designed to address the unmet needs of patients across the globe.
With each milestone we achieve, we move closer to transforming lives and redefining what is possible in healthcare.
Our pipeline reflects years of research, collaboration, and a relentless drive for excellence in pursuit of effective treatments. Join us on this journey as we continue to advance our therapies through clinical stages, aiming for FDA and global approvals that will bring these life-changing treatments to patients who need them most.

Contact

At Essen Biotech, we are committed to fostering connections with patients, healthcare professionals, researchers, and partners around the globe.
Whether you are interested in learning more about our therapies, participating in clinical trials, or exploring collaboration opportunities, our team is here to assist you. 

Contact Number: +44 7418621773

United Kingdom Regional Office

Contact Number: +973 17777166

Kingdom Of Bahrain Regional Office

Contact Number: +1 2077706670

United States Regional Office

Clinical Trials Department

Public Relations Department

Patient Support Department

ESSEN BIOTECH L.L.C. is a registered Biotechnology organization under the Delaware State Division of Corporations, with File Number 2669872. Please note that ESSEN BIOTECH does not have any laboratories outside of the United States of America but conducts clinical trials internationally. ESSEN BIOTECH L.L.C. will never contact you asking for any personal information. To view all available clinical trials, visit ClinicalTrials.gov. You can verify our official registration by visiting the Delaware Department of State: Division of Corporations at the following link: Delaware Entity Search.

X